Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa

Table 2 Effect of treatment for PAG compared with AG on PFS for the ECM biomarkers using the median cut-off point in stage 1 of HALO 109-202

Biomarker subgroup	HR	95% CI	P-value
C3M low	0.74	0.47–1.16	0.192
C3M high	0.70	0.33–1.45	0.332
C8-C^a low	0.72	0.38–1.38	0.323
C8-C^a high	0.56	0.21–1.45	0.231
PRO-C3 low	0.53	0.23–1.20	0.130
PRO-C3 high	0.88	0.43–1.80	0.735
PRO-C6 low	0.47	0.21–1.08	0.077
PRO-C6 high	1.07	0.53–2.17	0.853
VCANM^b low	0.63	0.32–1.23	0.176
VCANM^b high	0.73	0.30–1.74	0.725
C3M/PRO-C3 ratio low	1.09	0.55–2.18	0.807
C3M/PRO-C3 ratio high	0.40	0.17–0.92	0.031*

^aDetectable in 33% of samples
^bDetectable in 37% of samples
A univariate Cox regression analysis was used to calculate the predictive associations between biomarker levels and PFS. *A significant PFS benefit for PAG compared with AG was observed in the C3M/PRO-C3 ratio high subgroup (HR 0.40; 95% CI 0.17–0.92; P = .031). All other associations were non-significant

ISSN: 1479-5876